추천 제품
생물학적 소스
mouse
Quality Level
항체 형태
ascites fluid
항체 생산 유형
primary antibodies
클론
monoclonal
종 반응성
mouse, human
제조업체/상표
Chemicon®
기술
ELISA: suitable
immunocytochemistry: suitable
western blot: suitable
동형
IgG2a
NCBI 수납 번호
UniProt 수납 번호
배송 상태
wet ice
타겟 번역 후 변형
unmodified
유전자 정보
human ... CRABP2(1382)
특이성
Reacts with Cellular Retinoic Acid Binding Protein II (CRABPII). No cross reactivity with CRABPI.
면역원
Full length recombinant human CRABPII.
애플리케이션
Use Anti-CRABP2 Antibody (Mouse Monoclonal Antibody) validated in ELISA, WB, ICC to detect CRABP2 also known as Cellular Retinoic Acid Binding Protein II.
법적 정보
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
적합한 제품을 찾을 수 없으신가요?
당사의 제품 선택기 도구.을(를) 시도해 보세요.
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
Temporal blastemal cell gene expression analysis in the kidney reveals new Wnt and related signaling pathway genes to be essential for Wilms' tumor onset.
Maschietto, M; Trape, AP; Piccoli, FS; Ricca, TI; Dias, AA; Coudry, RA; Galante et al.
Cell Death & Disease null
L Delva et al.
Molecular and cellular biology, 19(10), 7158-7167 (1999-09-22)
Two sorts of proteins bind to, and mediate the developmental and homeostatic effects of, retinoic acid (RA): the RAR and RXR nuclear receptors, which act as ligand-dependent transcriptional regulators, and the cellular RA binding proteins (CRABPI and CRABPII). CRABPs are
Cutaneous clear cell squamous cell carcinoma in situ : clinical, histological and immunohistochemical characterization.
Munir Yahya Hussein Al-Arashi,H Randolph Byers
Journal of cutaneous pathology null
Epigenetic silencing of CRABP2 and MX1 in head and neck tumors.
Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, Pinheiro DG, Torres C et al.
Neoplasia null
Shuiliang Yu et al.
Journal of experimental & clinical cancer research : CR, 41(1), 88-88 (2022-03-10)
Resistance to standard therapy is a major reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Developing novel therapy to overcome PDAC drug-resistance is urgently needed. CRABP-II was highly expressed in all PDAC but not expressed in normal pancreatic
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.